Risultati della ricerca - Mocci, Simonetta

C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients di Patil, Namrata S., Zou, Wei, Mocci, Simonetta, Sandler, Alan, Ballinger, Marcus, Flynn, Susan, Kowanetz, Marcin, Hegde, Priti S.

Testo Testo Testo

Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatm... di Noé, Johannes, Bordogna, Walter, Archer, Venice, Smoljanovic, Vlatka, Hilton, Magalie, Woodhouse, Ryan, Mocci, Simonetta, Gadgeel, Shirish M.

Testo Testo Testo

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab di Vennapusa, Bharathi, Baker, Brian, Kowanetz, Marcin, Boone, Jennifer, Menzl, Ina, Bruey, Jean-Marie, Fine, Gregg, Mariathasan, Sanjeev, McCaffery, Ian, Mocci, Simonetta, Rost, Sandra, Smith, Dustin, Dennis, Eslie, Tang, Szu-Yu, Damadzadeh, Bita, Walker, Espen, Hegde, Priti S., Williams, J. Andrew, Koeppen, Hartmut, Boyd, Zachary

Testo Testo Testo

Laminin-411 Is a Vascular Ligand for MCAM and Facilitates TH17 Cell Entry into the CNS di Flanagan, Ken, Fitzgerald, Kent, Baker, Jeanne, Regnstrom, Karin, Gardai, Shyra, Bard, Frederique, Mocci, Simonetta, Seto, Pui, You, Monica, Larochelle, Catherine, Prat, Alexandre, Chow, Samuel, Li, Lauri, Vandevert, Chris, Zago, Wagner, Lorenzana, Carlos, Nishioka, Christopher, Hoffman, Jennifer, Botelho, Raquel, Willits, Christopher, Tanaka, Kevin, Johnston, Jennifer, Yednock, Ted

Testo Testo Testo

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1) di Kowanetz, Marcin, Zou, Wei, Gettinger, Scott N., Koeppen, Hartmut, Kockx, Mark, Schmid, Peter, Kadel, Edward E., Wistuba, Ignacio, Chaft, Jamie, Rizvi, Naiyer A., Spigel, David R., Spira, Alexander, Hirsch, Fred R., Cohen, Victor, Smith, Dustin, Boyd, Zach, Miley, Natasha, Flynn, Susan, Leveque, Vincent, Shames, David S., Ballinger, Marcus, Mocci, Simonetta, Shankar, Geetha, Funke, Roel, Hampton, Garret, Sandler, Alan, Amler, Lukas, Mellman, Ira, Chen, Daniel S., Hegde, Priti S.

Testo Testo Testo

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH) di Peters, Solange, Gettinger, Scott, Johnson, Melissa L., Jänne, Pasi A., Garassino, Marina C., Christoph, Daniel, Toh, Chee Keong, Rizvi, Naiyer A., Chaft, Jamie E., Carcereny Costa, Enric, Patel, Jyoti D., Chow, Laura Q.M., Koczywas, Marianna, Ho, Cheryl, Früh, Martin, van den Heuvel, Michel, Rothenstein, Jeffrey, Reck, Martin, Paz-Ares, Luis, Shepherd, Frances A., Kurata, Takayasu, Li, Zhengrong, Qiu, Jiaheng, Kowanetz, Marcin, Mocci, Simonetta, Shankar, Geetha, Sandler, Alan, Felip, Enriqueta

Testo Testo Testo